Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      Pathogenesis of Mood Disorders
      loading

      Chapter

      Pathogenesis of Mood Disorders

      DOI link for Pathogenesis of Mood Disorders

      Pathogenesis of Mood Disorders book

      The Neuroinflammatory Hypothesis

      Pathogenesis of Mood Disorders

      DOI link for Pathogenesis of Mood Disorders

      Pathogenesis of Mood Disorders book

      The Neuroinflammatory Hypothesis
      ByDr. Ather Muneer
      BookMood Disorders

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 2018
      Imprint Routledge
      Pages 19
      eBook ISBN 9781315149349
      Share
      Share

      ABSTRACT

      Mounting evidence from clinical and preclinical studies incriminates inflammation as a critical mediator in the pathophysiology of mood disorders. Indeed, elevated levels of proinflammatory cytokines have been repeatedly demonstrated in both major depressive disorder and bipolar disorder. Moreover, the induction of a proinflammatory state, for example by injecting lipopolysacchride in healthy subjects induces “sickness behavior”, resembling depressive symptomatology. Potential mechanisms include pathologic microglial cell activation, impaired neuroplasticity and structural and functional brain changes. Neuroinflammation is a condition in which brain tissue is effected by a chronic, low-grade inflammation. While cytokines are the chief mediators, ensuing changes in tryptophan metabolism and increased oxidative stress start a vicious cycle, resulting in apoptosis of neurons in crucial mood regulating areas of the brain. Newer psychopharmacological drugs appear to decrease the neuroinflammatory process, and efficacious treatments are associated with a reduction in inflammatory markers, both peripherally and centrally. Further, anti-inflammatory agents such as acetyl-salicylic acid, celecoxib, anti-TNF-α therapies, minocycline, curcumin and omega-3 fatty acids are being re-purposed for use in mood disorders. While there is selected evidence of efficacy for these agents in an adjunctive role, further research is necessary to establish their therapeutic benefit. There is a great need for novel medications which aim at the biological pathways that lead to the development of mood disorders, and targeting inflammation is an important strategy in ameliorating these conditions, as well as the accompanying comorbidities.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited